A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma

被引：0
|
作者：
Huang, Wendy E. [1 ]
Archer, Christine [1 ]
Yip, Desmond [1 ,2 ]
Kanjanapan, Yada [1 ,2 ]
Peters, Geoffrey [1 ,2 ]
机构：
[1] Canberra Hosp, Dept Med Oncol, Garran, ACT, Australia
[2] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
324
引用
下载
收藏
页码：173 / 174
页数：2
相关论文
共 50 条
  • [31] Clinical predictors of survival in real world practice in stage IV melanoma
    Hu, Hsien-Pang
    Archer, Christine
    Yip, Desmond
    Peters, Geoffrey
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 181 - 182
  • [32] Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
    Eggermont, Alexander M. M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew
    Lichinitser, Mikhail
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Maio, Michele
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul
    Ibrahim, Nageatte
    Marreaud, Sandrine
    van Akkooi, Alexander C. J.
    Suciu, Stefan
    Robert, Caroline
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19): : 1789 - 1801
  • [33] NETWORK META-ANALYSIS UNDER SURVIVAL HETEROGENEITY WITH LONG-TERM SURVIVAL: A CASE STUDY FROM ADJUVANT TREATMENT OF RESECTED STAGE III/IV MELANOMA
    Toor, K.
    Goring, S.
    Chan, K.
    Kurt, M.
    Moshyk, A.
    Hamilton, M.
    Kotapati, S.
    Jansen, J. P.
    VALUE IN HEALTH, 2022, 25 (01) : S208 - S208
  • [34] Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD1 Agents in Stage III/IV Resected Melanoma
    Roccuzzo, Gabriele
    Fava, Paolo
    Astrua, Chiara
    Brizio, Matteo Giovanni
    Cavaliere, Giovanni
    Bongiovanni, Eleonora
    Santaniello, Umberto
    Carpentieri, Giulia
    Cangiolosi, Luca
    Brondino, Camilla
    Pala, Valentina
    Ribero, Simone
    Quaglino, Pietro
    CANCERS, 2024, 16 (17)
  • [35] Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma
    Long, Georgina, V
    Luke, Jason J.
    Fukunaga-Kalabis, Mizuho
    Asierto, Paolo A.
    LANCET ONCOLOGY, 2023, 24 (01): : E8 - E8
  • [36] 3-Year Results Adjuvant Nivolumab Therapy continues to show longer recurrence-free Survival in High-risk Patients with resected Melanoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (12) : 703 - 703
  • [37] Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
    Egeler, Mees
    Lai-Kwon, Julia
    Tissier, Renaud
    Fraterman, Itske
    Kuijpers, Anke
    Van Houdt, Winan
    Wilgenhof, Sofie
    Rao, Aparna
    Sandhu, Shahneen
    Lee, Rebecca
    Eriksson, Hanna
    van Leeuwen, Marieke
    de Ligt, Kelly
    van Akkooi, Alexander
    van de Poll-Franse, Lonneke
    EUROPEAN JOURNAL OF CANCER, 2024, 200
  • [38] Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
    Patel, S.
    Othus, M.
    Prieto, V.
    Lowe, M.
    Buchbinder, E.
    Chen, Y.
    Hyngstrom, J.
    Lao, C. D.
    Truong, T-G.
    Chandra, S.
    Kendra, K.
    Devoe, C.
    Hedge, A.
    Mangla, A.
    Sharon, E.
    Korde, L.
    Moon, J.
    Sondak, V.
    Ribas, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1408 - S1408
  • [39] Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma
    Ridolfi, L
    Ridolfi, R
    Riccobon, A
    De Paola, F
    Petrini, M
    Stefanelli, M
    Flamini, E
    Ravaioli, A
    Verdecchia, GM
    Trevisan, G
    Amadori, D
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (02): : 156 - 162
  • [40] The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma
    Arak, Haci
    Erkilic, Suna
    Yaslikaya, Sendag
    Mocan, Eda Eylemer
    Aktas, Gokmen
    Ozdemir, Melek
    Semiz, Huseyin Salih
    Kilickap, Saadettin
    Ozalp, Faruk Recep
    Sever, Ozlem Nuray
    Akdag, Goncagul
    Agaoglu, Ahmet Burak
    Ozcelik, Melike
    Sari, Murat
    Arcagok, Murat
    Anik, Hicran
    Yayla, Saziye Burcak
    Sever, Nadiye
    Acar, Fatma Pinar
    Bayrakci, Ismail
    Turhal, Serdar
    Ayhan, Murat
    Kus, Tulay
    JOURNAL OF IMMUNOTHERAPY, 2024, 47 (05) : 182 - 189
12345